Become A Featured Company

Creso Pharma’s Plans Progress as Israel’s New Medical Cannabis Export Law Passed by Parliament

Ryan Allway

January 2nd, 2019

News

  • Israel’s Parliament approves law for exporting medicinal cannabis as well as a new
    regulatory structure to approve foreign ownership of Israeli medicinal cannabis operations
  • Creso is well positioned to take advantage of these changes via its 74% stake in a Joint
    Venture with Israeli-based Cohen Propagation Nurseries Ltd (“Cohen”)
  • This brings to life Creso’s plan to grow and export medical grade cannabis from Israel
  • Israel’s human capital, research know-how, exceptional skill base and start up mentality
    underpins enormous opportunities in this field.

Creso Pharma Limited (ASX: “CPH”, the “Company” or “Creso”) is pleased to announce its
strategic plan is a step closer with the Israeli Parliament’s approval to allow the export of medicinal cannabis from Israel. The new law will allow Israel to participate in the global medicinal cannabis industry once it receives Israeli Cabinet sign off.

Creso is well positioned to take advantage of these changes via its 74% stake in a Joint Venture
with Israeli-based Cohen nurseries. The JV will enable Creso to supply cannabis strains previously unavailable from Israeli cannabis producers.

Creso is one of few ASX traded company with operations in Israel and one of only a few Licensed Producers in Canada with access to Israeli strains. Recently Dr Sanjay Gupta, Chief Medical Correspondent for the Health, Medical and Wellness unit at CNN1 stated: “Israel is the marijuana research capital of the world.” Israeli Agriculture Minister Uri Ariel said: “The Israeli research conditions for growth in the field precede most of the countries in the world by five to seven years because of progressive regulation.”2

According to Michael Dor, Senior Medical Adviser at the Ministry of Health’s Medical Cannabis
Unit, “Right now, there are more than one hundred and ten clinical trials involving cannabis
underway in Israel, more than any other country. Many of those studies are funded by the Israeli government.” 2

This wealth of clinical research has resulted in the development of strains designed to treat specific ailments backed by hard research data, which is missing in most medicinal cannabis product claims. Dr. Miri Halperin Wernli, Creso’s CEO and Co-Founder has welcomed the new law and supports Israel joining the leading global export nations of medical cannabis. Said Dr Halperin Wernli: “Creso plans to access these exciting new proprietary Israeli strains which can also now be exported, either as whole plant or raw genetics to our own internal operations or to external licensed producers. “The legislation removes the last legal obstacle for medicinal cannabis exports and we look forward to taking advantage of Israel’s cutting edge technology and access to high-quality, well researched medicinal cannabis. “As a vertically integrated cannabis company with CBD products already commercialised and cannabis cultivation soon to start production in Canada as well as Colombia and Israel, Creso’s strategy is rapidly coming together to form a powerful enterprise actively participating in the global cannabis market which is projected to reach $60 billion by 2024.”

Creso is becoming an increasingly bigger global participant in the human and animal CBD
supplement market which is expected to exceed $350 billion by 2024. 3

Founded in 1958, Cohen is one of the most experienced agricultural companies in Israel and hassignificant operational know-how and proven capabilities in establishing high scale production greenhouses to international standards. Cohen owns and operates farms across south and central Israel with a total greenhouse capacity of 15.7 hectares / 38.7 acres. Creso conservatively estimates annual production of up to 2,500 kilograms of high-quality cannabis
per year from Cohen once the facility is at full capacity.

Licensed cannabis growers are expected to begin exporting medical cannabis products from Israel by mid-2019. Saul Kaye, CEO of iCAN recently stated: “The worldwide medical cannabis market is estimated to generate $33 billion dollars over the next five years with Israel expecting to rack up over $1 billion in export sales. Among the countries reportedly eager to trade with Israel include Australia, Germany, Austria and Mexico.” 4

In a country known to Wall Street as “Start-up Nation”, Israel is perfectly positioned to expose and take advantage of the growing opportunities in the sector. Importantly, Israel has the human capital, research know-how, skill base and start up mentality to excel and lead the field. With the new law passing Parliament the way is paved for cannabis to potentially become as important to Israel’s economy as technology.1

1 https://www.thegrowthop.com/cannabis-health/cannabis-medical/israeli-legislation-paves-the-way-for-exporting-medical-cannabis-in-
2019

2 https://mjbizdaily.com/israeli-parliament-approves-medical-cannabis-exports/

3 https://www.brightfieldgroup.com/post/hemp-cbd-market-to-reach-22-billion-by-2022-outpacing-the-rest-of-the-cannabis-market-
combined

4 https://www.forbes.com/sites/irisdorbian/2018/12/26/israeli-lawmakers-approve-law-to-export-medical-cannabis/#511bf3fb6806

Investor and Media Enquiries:
EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW
2000
E: info@everblucapital.com

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings
pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About Cohen Propagation Nurseries Limited

Cohen Propagation Nurseries is a family business, established in 1958. Located in the centre of
Israel and spread over 3 different farms in Kfar Hanagid, Gderot and Nir Hen the company employs a 550 highly trained staff working across a total greenhouse area of 15.7 hectares.
Cohen’s products are famous for their high quality, sterility and hygiene and are supplied with a
special quality certificate from Israel’s Ministry of Agriculture Plant Protection and Inspection
Services. Cohen has been exporting cuttings for both bedding and basket plants since 1979.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.
The cautionary statements qualify all forward-looking statements attributable to Creso and persons. acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading